gper1 Antibody

What is GPER1 and why are antibodies important for its study?

GPER1 is a membrane-bound estrogen receptor belonging to the G-protein coupled receptor (GPCR) superfamily. It contains seven membrane-spanning domains with an extracellular N-terminus and a cytoplasmic C-terminal domain, and binds 17β-estradiol with high affinity . Antibodies are essential tools for GPER1 research because they allow detection, localization, and functional characterization of this receptor in various experimental contexts.

GPER1 activation has several beneficial effects in multiple systems including:

• Cardiovascular system: vasorelaxation, inhibition of smooth muscle cell proliferation, and myocardial protection against ischemia/reperfusion injury

• Metabolic system: stimulation of insulin release and protection against pancreatic β-cell apoptosis

As GPER1 has diverse physiological roles, reliable antibodies are critical for understanding its distribution and function in normal and pathological conditions.

What types of GPER1 antibodies are available for research?

Several types of GPER1 antibodies have been developed for research purposes:

• C-terminus targeting antibodies: Including rabbit polyclonal antibodies against synthetic peptides derived from the C-terminus of the human GPER1 polypeptide (e.g., CAVIPDSTEQSDVRFSSAV) . These recognize the 38 kDa band corresponding to the mature 351 amino acid GPER1 polypeptide.

• N-terminus targeting antibodies: Such as the polyclonal goat anti-GPER antibody AF5534 (R&D systems), which is directed against the N-terminal tail of GPER .

• Extracellular domain targeting antibodies: For example, antibodies against peptide CKQSFRHAYPLTGH, corresponding to amino acid residues 294-307 of mouse GPER1, located in the 3rd extracellular loop .

• Monoclonal antibodies: Such as the rabbit monoclonal anti-human GPER antibody 20H15L21, which has been shown to provide more distinct immunosignal with less non-specific nuclear and background staining compared to polyclonal antibodies .

Each antibody type has specific applications and validation requirements for optimal experimental outcomes.

How can I determine the specificity of my GPER1 antibody?

Determining antibody specificity is crucial for reliable results. Multiple complementary approaches should be used:

• Western blot analysis: Use positive controls (GPER-transfected cell lines) and negative controls (mock-transfected cells that don't express GPER1). Specific antibodies should recognize bands at expected molecular weights (~35, 40, and 55-70 kDa depending on glycosylation status) in positive controls but not in negative controls .

• Preadsorption experiments: Preincubate the antibody with the immunizing peptide. This should completely abolish the immunosignal if the antibody is specific. As a control, preincubation with an unrelated peptide should not affect signal intensity .

• siRNA knockdown: In cells expressing endogenous GPER1, transfection with GPER1-specific siRNA should dramatically reduce antibody signal, while control siRNA should not affect detection .

• Immunostaining in known positive/negative tissues: Compare staining patterns with reported GPER1 expression in various tissues. The immunosignal should be consistently detected in tissues known to express GPER1 .

• Correlation with mRNA expression: Compare protein detection with qRT-PCR measurements of GPER1 mRNA in the same samples to verify correlation between transcript and protein levels .

These validation approaches collectively provide strong evidence for antibody specificity.

How do I distinguish between different glycosylated forms of GPER1 in Western blots?

GPER1 exists in different glycosylated states that appear as distinct bands on Western blots. Proper identification requires understanding these different forms:

• 40 kDa species: This represents the predominant form in most non-enriched cellular preparations. It corresponds to an immature form of GPER1 that matures slowly and remains largely linked to the endoplasmic reticulum .

• 55-70 kDa species: This represents the fully mature glycosylated form of GPER1 that is transferred to the plasma membrane. This form may require wheat germ lectin agarose (WGA) bead enrichment to be detected in Western blots due to its relatively low abundance .

• 35 kDa species: This likely represents a proteolytically degraded form of the receptor .

To optimize detection of all forms:

• Use wheat germ lectin agarose (WGA) bead enrichment for low-abundance glycosylated species

• Include positive controls with known expression patterns

• Apply appropriate protein extraction methods that preserve glycosylation status

• Consider using deglycosylation enzymes (PNGase F) to confirm glycosylation status

The predominant detected form may vary depending on cell/tissue type and experimental conditions, so multiple controls are essential for accurate interpretation.

What strategies should I use to detect GPER1 subcellular localization, given contradictory reports in the literature?

The subcellular localization of GPER1 has been a subject of debate, with reports showing plasma membrane, endoplasmic reticulum, and other intracellular locations. To accurately determine GPER1 localization:

• Use multiple antibodies targeting different epitopes: Compare results from antibodies directed against extracellular (N-terminal or loop regions) and intracellular (C-terminal) domains .

• Apply complementary techniques:

  • Immunofluorescence microscopy with subcellular markers (e.g., plasma membrane, ER, Golgi markers)

  • Cell fractionation followed by Western blotting

  • Electron microscopy with silver-enhanced immunogold (SIG) labeling for precise ultrastructural localization

• Implement live-cell labeling: For cell surface detection in intact cells, use antibodies targeting extracellular epitopes without cell permeabilization .

• Evaluate effects of ligands on localization: Test how GPER1 agonists (e.g., G-1) and antagonists (e.g., G-15) affect receptor distribution. Research shows G-15 treatment can shift GPER1 predominantly to the plasma membrane .

• Validate with GPER1 knockout/knockdown controls: Use genetic models (knockout mice) or siRNA knockdown to confirm specificity of subcellular staining patterns .

The combined approach provides a more reliable picture of GPER1 distribution and can help reconcile contradictory findings reported in the literature.

How should I design experiments to assess GPER1 antibody cross-reactivity with ERα and ERβ?

Cross-reactivity with classical estrogen receptors (ERα and ERβ) is a critical concern for GPER1 antibody specificity. A comprehensive experimental design should include:

• Western blot analysis with purified proteins: Test antibody against recombinant GPER1, ERα, and ERβ proteins to assess direct cross-reactivity .

• Cell line panels with defined receptor expression:

  • Use cell lines expressing only GPER1 but not ERα/ERβ (e.g., SKBR3)

  • Compare with cells expressing ERα/ERβ but not GPER1

  • Include triple-negative control cells

• Competitive binding assays: Determine if specific ERα/ERβ ligands compete with antibody binding to GPER1.

• Immunoprecipitation followed by mass spectrometry: Confirm that antibodies specifically pull down GPER1 and not ERα/ERβ.

• Tissue from receptor knockout models: Compare staining in wild-type versus GPER1, ERα, or ERβ knockout tissues to verify selective detection .

The polyclonal antibody against the C-terminus of GPER1 was reported not to recognize either ERα or ERβ on Western blots, providing a good baseline for comparison with other antibodies .

What are the optimal fixation and tissue preparation methods for GPER1 immunohistochemistry?

Proper tissue fixation and preparation are critical for reliable GPER1 detection. Based on the literature, the following protocols have proven effective:

• For brain tissue:

  • Perfusion fixation with 4% paraformaldehyde preserves GPER1 immunoreactivity

  • Alternative fixation with acrolein/paraformaldehyde mixture has been successfully used for electron microscopy studies

  • Post-fixation time should be optimized (typically 24-48 hours)

• For peripheral tissues:

  • Standard formalin fixation followed by paraffin embedding works well for most tissues

  • Overfixation should be avoided as it may mask epitopes

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) is often necessary

  • Optimization of retrieval conditions (temperature, time, buffer) may be required for different antibodies

• Blocking conditions:

  • 0.5% bovine serum albumin (BSA) in Tris-buffered saline effectively reduces background

  • Additional blocking with normal serum matching the host of the secondary antibody improves specificity

• Detection systems:

  • For light microscopy: peroxidase-avidin complex with 3,3′-diaminobenzidine (DAB)

  • For electron microscopy: silver-enhanced immunogold (SIG) technique

These methods should be systematically compared and optimized for your specific tissue and antibody combination.

How can I quantitatively measure GPER1 expression in tissue samples?

Quantitative assessment of GPER1 expression requires standardized approaches:

• Immunohistochemistry quantification:

  • Immunoreactive scoring system (IRS) combining staining intensity and percentage of positive cells

  • Digital image analysis with standardized acquisition parameters

  • Quantitative densitometry using image analysis software (e.g., NIH ImageJ)

  • Use matched sections processed in the same batch

• Western blot quantification:

  • Normalize GPER1 signal to appropriate loading controls

  • Consider wheat germ lectin agarose (WGA) bead enrichment for detecting low-abundance forms

  • Use standard curves with recombinant GPER1 for absolute quantification

• Correlation with mRNA expression:

  • Perform qRT-PCR for GPER1 mRNA isoforms (e.g., isoforms 2 and 3+4)

  • Analyze correlation between protein and mRNA levels

  • Note that correlation may not always be strong due to post-transcriptional regulation

• Receptor binding assays:

  • Membrane filtration assay to measure specific estrogen binding to plasma membranes

  • Determine binding parameters (affinity, capacity) using radioligand binding

For quantitative densitometry, it's crucial to control for uneven illumination (by subtracting blank fields), use standardized camera settings, and apply blind analysis of coded slides to minimize bias .

What controls are essential when validating a new batch of GPER1 antibody?

When validating a new antibody batch, comprehensive controls are essential:

• Positive and negative tissue/cell controls:

  • Known GPER1-expressing tissues (e.g., specific brain regions, breast tissue)

  • GPER1-transfected versus mock-transfected cell lines

  • GPER1 knockout tissue when available

• Peptide preadsorption controls:

  • Preincubate antibody with the immunizing peptide at sufficient concentration (e.g., 10 μg/ml)

  • Compare with preincubation using an unrelated peptide from a different region of GPER1

• siRNA knockdown validation:

  • Transfect cells with GPER1-specific siRNA and compare staining with non-transfected cells

  • Include non-targeting siRNA as control

• Batch-to-batch comparison:

  • Directly compare new batch with previously validated batches on identical samples

  • Document any differences in sensitivity or background

• Cross-platform validation:

  • Confirm results across multiple techniques (Western blot, immunocytochemistry, immunohistochemistry)

  • Correlate with mRNA expression by qRT-PCR

• Antibody dilution series:

  • Test multiple dilutions to determine optimal signal-to-noise ratio

  • Compare optimal dilution with manufacturer's recommendations

How do I interpret contradictory GPER1 antibody staining patterns in breast cancer tissues?

Contradictory GPER1 staining patterns in breast cancer have been reported in the literature . To properly interpret these conflicting results:

• Evaluate antibody specificity: Different antibodies may recognize different GPER1 epitopes or glycosylation states. Compare results from multiple validated antibodies targeting different regions of GPER1 .

• Consider heterogeneity factors:

  • Tumor heterogeneity within and between patients

  • Variation in breast cancer subtypes (ER+/-, PR+/-, HER2+/-)

  • Stage and grade of tumors

  • Prior treatment history (especially hormone therapy)

• Correlate with mRNA analysis:

  • Perform qRT-PCR for GPER1 mRNA isoforms on serial sections

  • Consider potential post-transcriptional regulation mechanisms

  • Analyze correlation between protein and transcript levels

• Standardize scoring systems:

  • Use established immunoreactive scoring (IRS) systems

  • Document both staining intensity and percentage of positive cells

  • Separate scoring for membrane versus cytoplasmic staining

• Functional validation:

  • Correlate GPER1 expression with downstream signaling markers

  • Analyze patient outcome data in relation to GPER1 expression patterns

Understanding these contradictions may yield insights into GPER1 biology in cancer and help reconcile disparate findings across research groups.

What are the implications of different molecular weight bands in GPER1 Western blots?

GPER1 appears as multiple bands in Western blots, reflecting different post-translational modifications. Proper interpretation requires understanding these patterns:

• Common band patterns and their significance:

  • 40 kDa band: Predominant form in most non-enriched preparations, representing an immature ER-associated form

  • 55-70 kDa bands: Mature, fully glycosylated forms primarily associated with plasma membrane localization

  • 35 kDa band: Likely represents proteolytically degraded forms

• Tissue/cell-specific variations:

  • Cell lines may predominantly express the 40 kDa form

  • In WGA bead-enriched preparations from GPER1-transfected cells, all three forms are typically visible

  • Normal human liver shows all three bands, suggesting tissue-specific regulation of receptor processing

• Experimental conditions affecting band patterns:

  • Sample preparation methods (detergents, reducing agents)

  • Glycosylation inhibitors can shift band patterns

  • Receptor ligands may affect receptor processing and degradation

• Analytical approaches:

  • Deglycosylation experiments with PNGase F to confirm glycosylation status

  • Pulse-chase studies to track maturation of different receptor forms

  • Subcellular fractionation to correlate band patterns with receptor localization

Understanding these band patterns is crucial for studies investigating GPER1 trafficking, maturation, and signaling in different physiological and pathological contexts.

How do I resolve discrepancies between GPER1 protein detection and functional assays?

Researchers often encounter situations where GPER1 protein detection does not align with functional responses. To reconcile these discrepancies:

• Evaluate receptor functionality versus expression:

  • Not all detected receptors may be functionally active

  • Post-translational modifications may affect functionality without changing antibody recognition

  • Different glycosylated forms (35, 40, and 55-70 kDa) may have different signaling capabilities

• Consider receptor compartmentalization:

  • GPER1 in different subcellular locations may have different signaling properties

  • Plasma membrane GPER1 may respond differently than intracellular receptors

  • Investigate how GPER1 agonists (G-1) and antagonists (G-15) affect receptor localization

• Assess signaling pathway components:

  • Check for expression/activity of downstream effectors (Gβγ-protein subunits, Src-like kinases)

  • Evaluate engagement of integrin α5β1, which is necessary for EGFR transactivation

  • Analyze formation of provisional fibronectin matrix, which is coordinated by GPER1

• Experimental approach integration:

  • Combine protein detection with calcium mobilization assays

  • Measure EGFR transactivation and downstream ERK1/2 phosphorylation

  • Correlate receptor levels with physiological endpoints (e.g., cell proliferation, migration)

• Genetic validation approaches:

  • Use CRISPR/Cas9 to confirm phenotypes are truly GPER1-dependent

  • Rescue experiments with wild-type versus mutant GPER1 constructs

Integrating multiple experimental approaches provides a more comprehensive understanding of GPER1 biology and resolves apparent discrepancies between detection and function.

What steps should I take to troubleshoot weak or absent GPER1 signal in Western blots?

When facing challenges with GPER1 detection in Western blots:

• Sample preparation optimization:

  • Try wheat germ lectin agarose (WGA) bead enrichment, which significantly enhances detection of glycosylated GPER1 forms

  • Use appropriate lysis buffers containing proper detergents (e.g., Triton X-100, CHAPS)

  • Include protease inhibitors to prevent degradation

  • Avoid excessive heating which may cause aggregation of membrane proteins

• Protein loading and transfer:

  • Increase protein loading (up to 50-100 μg)

  • Optimize transfer conditions for membrane proteins (longer transfer times, lower methanol percentage)

  • Use PVDF membrane instead of nitrocellulose for better protein retention

  • Consider semi-dry versus wet transfer methods

• Antibody conditions:

  • Test different antibody concentrations (typically 1:200 to 1:2000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Try different blocking reagents (BSA may be better than milk for some epitopes)

  • Use more sensitive detection systems (enhanced chemiluminescence)

• Band visualization strategies:

  • For endogenous expression in cell lines like A431, focus on detecting the 40 kDa species

  • The 55-70 kDa and 35 kDa species may require enrichment to be visible

  • Consider stain-free technology for total protein normalization instead of traditional housekeeping proteins

Following this systematic approach will help identify and overcome technical limitations in GPER1 Western blot detection.

How can I minimize non-specific background in GPER1 immunohistochemistry?

Non-specific background can complicate interpretation of GPER1 immunostaining. To improve signal-to-noise ratio:

• Antibody selection and optimization:

  • Monoclonal antibodies (e.g., 20H15L21) often provide more distinct immunosignal with less non-specific nuclear and background staining compared to polyclonal antibodies

  • Titrate antibody concentration to determine optimal working dilution

  • Consider direct labeling approaches to eliminate secondary antibody issues

• Blocking optimization:

  • Use 0.5% bovine serum albumin (BSA) in buffer solutions

  • Add normal serum matching the host of secondary antibody (typically 5-10%)

  • Consider specialized blocking reagents for tissues with high endogenous biotin or peroxidase

• Tissue preparation improvements:

  • Optimize fixation protocols (duration, type of fixative)

  • Test different antigen retrieval methods (heat-induced versus enzymatic)

  • Block endogenous peroxidase with hydrogen peroxide treatment before antibody application

• Technical refinements:

  • Use longer wash steps to remove unbound antibody

  • Apply avidin-biotin blocking for biotin-based detection systems

  • Compare DAB visualization with alternative chromogens

  • For fluorescence, include Sudan Black B treatment to reduce autofluorescence

• Controls for validating specificity:

  • Always include preadsorption controls with immunizing peptide

  • Use GPER1 knockout or knockdown samples as negative controls

  • Subtract background in image analysis using blank fields taken from slides lacking tissue

These strategies collectively enhance the specificity of GPER1 detection in tissue sections.

What approaches can help distinguish true GPER1 signal from artifacts in microscopy?

Distinguishing genuine GPER1 signal from artifacts requires multiple validation approaches:

• Comprehensive controls:

  • Antibody preadsorption with immunizing peptide (should eliminate specific signal)

  • Preadsorption with unrelated peptide (should not affect specific signal)

  • Primary antibody omission (to detect secondary antibody artifacts)

  • GPER1 knockout or knockdown samples (genetic validation)

• Multi-antibody confirmation:

  • Compare staining patterns with multiple antibodies targeting different GPER1 epitopes

  • The polyclonal antibodies ab39742 (Abcam) and AF5534 (R&D systems) can be compared with monoclonal antibody 20H15L21

  • Be aware that polyclonal antibodies may show more non-specific background staining

• Correlative microscopy:

  • Compare light microscopic immunoperoxidase labeling with electron microscopy

  • Silver-enhanced immunogold (SIG) technique provides ultrastructural localization

  • Super-resolution microscopy approaches can verify subcellular distribution

• Ligand-induced changes:

  • Compare staining before and after treatment with specific GPER1 agonists (G-1) or antagonists (G-15)

  • G-15 treatment was shown to shift the immunosignal predominantly to the plasma membrane

• Image acquisition standardization:

  • Use consistent camera settings and light levels across specimens

  • Implement blind analysis of coded slides

  • Apply appropriate image processing (adjusting levels, contrast, brightness) consistently